AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05405647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave Therapy
Description: a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
Study NCT05405647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
Study NCT05481866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum
Description: The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours.
Study NCT05481866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oropharyngeal administration of sterile water
Description: The control group will be given 0.2ml sterile water for oropharyngeal administration every 3 hours.
Study NCT04676048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASC618
Description: ASC618 will be given as a single IV infusion
Study NCT05116670 — intervention group
Intervention type: OTHER
Description: this is an observation study, no intervention is needed
Study NCT04462406 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ipilimumab
Description: Given IV
Study NCT05618873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter device
Description: The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
Study NCT05618873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positive expiratory pressure mask
Description: The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times.
Study NCT05708001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
Study NCT05708001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography (hdEEG)
Description: EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
Study NCT05708001 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline, after 4 weeks and 12 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
Study NCT05782829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-tyrosine supplementation
Description: L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
Study NCT05782829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Placebo supplementation before surgery for inguinal hernia under general anaesthesia
Study NCT06272344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation at 6 months
Study NCT04462406 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT04462406 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nivolumab
Description: Given IV
Study NCT04462406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo active surveillance
Study NCT04462406 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT04462406 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab
Description: Given IV
Study NCT06370416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
Study NCT00000815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuvax
Description: Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
Study NCT00000815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R-II
Description: Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
Study NCT05675137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile-based
Description: Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
Study NCT05675137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper-based
Description: Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
Study NCT04182867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention
Description: Dietary modification (provision of diet).
Study NCT04182867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary modification (provision of diet).
Study NCT06435702 — intervention group
Intervention type: DRUG
Intervention: Darolutamide in addition to androgen deprivation therapy
Description: Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
Study NCT06435702 — intervention group
Intervention type: DRUG
Intervention: androgen deprivation therapy only
Description: The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
Study NCT05772637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated cystometries with bladder sensations assessment
Description: A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
Study NCT06446557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment adaptation guided by ctDNA variation
Description: after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA.
Study NCT06446557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard management
Description: At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
Study NCT05438667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T therapy
Description: 1.Preprocessing strategy：~1. Cyclophosphamide: 500mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 14 days (24 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed .
Study NCT04819906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol 20 mg
Description: One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
Study NCT04819906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol 100 mg
Description: Five estetrol monohydrate (E4) 20 mg tablets orally once
Study NCT04819906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Five placebo tablets orally once
Study NCT04819906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: One moxifloxacin 400 mg tablet orally once (open-label)
Study NCT05286606 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise and Social Groups
Description: Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support.
Study NCT05840939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama
Description: Pranayama, one of the practices of yoga, is a Sanskrit word consisting of a combination of two words, a technique of rhythmic, controlled breathing. So prana means life breath/life energy and ayama means expansion/regulation/control. Pranayama helps to improve lung capacity, heart and respiratory functions, nervous and hormonal systems, as well as mental activity.
Study NCT05840939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diaphragm breathing exercise
Description: Diaphragmatic breathing is also known as deep breathing or slow abdominal breathing. This breathing exercise uses the diaphragm muscle. The diaphragm is the muscle under the lungs that supports the lungs in up and down breathing.
Study NCT06199245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional freedom technique experimental group
Description: Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
Study NCT04865965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Bout of Exercise
Description: Exercising for 60 minutes at 55-60% of VO₂ peak
Study NCT05965674 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Plane Block
Description: The transducer will be placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) will be injected between the erector spinae muscles and the intermediate sacral crest. The same procedure will be performed on the contralateral side.
Study NCT05187832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND019 PO QD
Description: AND019 administrated as oral capsule once per day for 28 days for each cycle
Study NCT04947527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test varnish
Description: A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
Study NCT04947527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
Study NCT05320575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
Study NCT04230447 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04193930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Oral tablet letrozole 2,5 mg/twice daily for 5 days
Study NCT04193930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Menotropins
Description: 150 IU of highly purified menotropins intramuscular
Study NCT04193930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: recombinant Follicular stimulating hormone
Description: recombinant Follicular stimulating hormone 300- 400 IU
Study NCT04965740 — intervention group
Intervention type: DRUG
Intervention: Cannabis
Description: Recreational Cannabis
Study NCT05729009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin microvascular reactivity
Description: Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
Study NCT05927883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenously Adapted Cognitive Behavioral Therapy
Description: IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
Study NCT05927883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indigenously Adapted Cognitive Behavioral Therapy
Description: IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
Study NCT06335615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Acceptance Intervention
Description: The intervention consist of explanations and exercises about acceptance of stress. The intervention starts with a welcome, after which participants do jumping jacks and then breath through a straw to induce an uncomfortable experience. Next, a Chinese finger trap is used to show the automatic, but often not useful, reaction to avoid stress. Participants then watch a short video that introduces the concept of acceptance, and they do a short, guided meditation. Afterwards, they do the straw exercise again, but this time with instruction to examine and allow uncomfortable experiences. The session ends with a recap and the introduction of the home exercise. Participants install an app that reminds them every hour to do a three-second meditation in which they pay attention to their breathing and body in an accepting way.
Study NCT06335615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: In the psychoeducation, participants learn about the stress response, mindfulness, and acceptance. For this, they are guided through a vignette about a student who struggles with stress and then develops a more accepting stance towards it. The psychoeducation explains how acceptance can help to deal with stress but does not instruct participants to apply this in their own life.
Study NCT04915196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Liposomally-bound Iron
Description: Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
Study NCT05873985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic tape on experimental group
Description: The dynamic taping application was carried out in 2 stages. Three I-shaped tapes were cut. In the first stage, the person was asked to perform scapular retraction, and in this position, the tape was placed by applying medium tension to the anterior part of the other deltoid muscle, passing from the anterior part of the deltoid muscle to the upper thoracic region. In the second stage, the participant was asked to do scapular retraction and depression, and while maintaining this position, medium tension was applied to the lower thoracic vertebra starting from the anterior part of the deltoid muscle and the acromion and tape was applied. Afterward, this process was applied on the other side
Study NCT05873985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham tape on placebo group
Description: Sham taping was performed in 2 stages. Three I-shaped tapes were cut. Participants were asked to stand in the comfortable position they used during the day. The first tape was adhered from the starting point of the spine of the scapula with the acromion to the junction of the spine of the scapula and the acromion on the other side without any tension. The other two tapes, starting from the beginning and ending points of the first tape, were adhered to the lower thoracic region without any tension
Study NCT05352542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC3 Targeting CART Cells
Description: before treatment with GPC3 Targeting CART cells, subjects will receive a conditioning regimen
Study NCT05998915 — intervention group
Intervention type: OTHER
Intervention: observe only
Description: observe only
Study NCT04947644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects